There are various modes of anti-fungal drug delivery that increases adoption of this products leading to high growth of this market. In addition, absorption of drugs works differently for each individual. Hence, advancement in drug delivery technology is expected to boost the growth of the global antifungal drug market. Further, growing incidence and prevalence rate of infectious diseases and growth in population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period.
The global antifungal drugs market is segmented based on drug type, therapeutic indications, infection type, and geography. Based on drug type, the market is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. Further, based on therapeutic indications, it is classified into aspergillosis, dermatophytosis, candidiasis, others. Based on infection type, the market is bifurcated into superficial and systemic antifungals.
Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals, However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.
KEY MARKET BENEFITS
The study provides an in-depth analysis of the global antifungal drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry, which helps understand the type of products and technologies used globally, is also included.
Key market players and their strategies are provided to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Drug Type
By Infection Type
Superficial Antifungal Infections
Systemic Antifungal Infections
By Therapeutic Indications
By Dosage Forms
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
KEY PLAYERS PROFILED
Gilead Sciences, Inc.
Merck & Co., Inc.
Novartis International AG
Enzon Pharmaceuticals, Inc.
The other players in the value chain include (profiles not included in the report)
Agilent Technologies, Inc.
Beckman Coulter, Inc. (a subsidiary of Danaher Corporation)
Astellas Pharma, Inc.
Basilea Pharmaceutical Ltd.
Valeant Pharmaceuticals International, Inc.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
184.108.40.206. Increasing prevalence of fungal infection
220.127.116.11. Rising awareness levels pertaining to myriad fungal infections
18.104.22.168. Favorable government funds to combat the antifungal diseases
22.214.171.124. Growing population with antifungal drug resistance
126.96.36.199. Presence of counterfeit drugs and side effects of antifungal drugs
188.8.131.52. Patent expirations and increasing funding from public & private organizations
CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
4.1.1. Market size and forecast
4.2. SUPERFICIAL ANTIFUNGAL INFECTION
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SYSTEMIC ANTIFUNGAL INFECTION
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE
5.1.1. Market size and forecast
5.2.1. Market size and forecast
184.108.40.206. Market size and forecast
220.127.116.11. Market size and forecast
18.104.22.168. Market size and forecast
22.214.171.124. Market size and forecast
5.3.1. Market size and forecast
126.96.36.199. Market size and forecast
188.8.131.52. Market size and forecast
184.108.40.206. Market size and forecast
220.127.116.11. Market size and forecast
5.4.1. Market size and forecast
5.4.2. Amphotericin B
18.104.22.168. Market size and forecast
22.214.171.124. Market size and forecast
126.96.36.199. Market size and forecast
188.8.131.52. Market size and forecast
184.108.40.206. Market size and forecast
5.5.1. Market size and forecast
220.127.116.11. Market size and forecast
18.104.22.168. Market size and forecast
22.214.171.124. Market size and forecast
5.6.1. Market size and forecast
CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
6.1.1. Market size and forecast
6.2.1. Market size and forecast
6.3.1. Market size and forecast
6.4.1. Market size and forecast
6.5.1. Market size and forecast
CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
7.1.1. Market size and forecast
7.2.1. Market size and forecast
7.3.1. Market size and forecast
7.4.1. Market size and forecast
7.5.1. Market size and forecast
CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
126.96.36.199. U.S. market size and forecast
188.8.131.52. Mexico market size and forecast
184.108.40.206. Canada market size and forecast
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
220.127.116.11. UK market size and forecast
18.104.22.168. France market size and forecast
22.214.171.124. Germany market size and forecast
126.96.36.199. Italy market size and forecast
188.8.131.52. Spain market size and forecast
184.108.40.206. Rest of Europe market size and forecast
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
220.127.116.11. Japan market size and forecast
18.104.22.168. China market size and forecast
22.214.171.124. India market size and forecast
126.96.36.199. Australia market size and forecast
188.8.131.52. Rest of Asia-Pacific market size and forecast
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
184.108.40.206. Brazil market size and forecast
220.127.116.11. Argentina market size and forecast
18.104.22.168. Saudi Arabia market size and forecast
22.214.171.124. South Africa market size and forecast
126.96.36.199. Rest of LAMEA market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1. PFIZER INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. SANOFI S.A
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. GILEAD SCIENCES INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments
9.4. MERCK & CO., INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments
9.5. NOVARTIS INTERNATIONAL AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments
9.6. ABBOTT LABORATORIES
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments
9.7. BAYER AG
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. SCYNEXIS INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. ENZON PHARMACEUTICALS INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. GLAXOSMITHKLINE PLC
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.
The growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad fungal infections, and increase in demands of generic drugs are the major factors that drive the market growth. However, patent expiration of branded therapeutics and presence of counterfeit drugs restrain the growth of the antifungal drugs market. In addition, increase in R&D expenditure coupled with funding from the public & private sector is expected to provide lucrative growth opportunities to the antifungal drugs market.
The systemic antifungals segment is anticipated to maintain its dominance during the forecast period, accounting for about fifth-sevenths share of the global antifungal drugs market in 2016. This is due to the high usage of drugs such as azole for all the fungal indications and these also offer broad spectrum activity and improved safety levels. In addition, rise in prevalence of most commonly occurring systematic fungal infection such as candidiasis supplements the market growth. However, the superficial antifungals are expected to grow rapidly throughout the forecast period. This is because of the growth in incidence of hospital-acquired infections and increase in life expectancy among people.
The dermatophytosis indication is expected to register the highest CAGR of 4.1% throughout the forecast period. This is because of high incidences of skin infections in both children and adults. Candidiasis indication generated the highest revenue in 2016, accounting for about one-third of the total share in 2016, and is anticipated to maintain this trend from 2017 to 2023.
Key Findings of the Antifungal Drugs Market:
The superficial antifungals are anticipated to grow at a highest rate during the analysis period.
The U.S. was the major shareholder in the North America antifungal drugs market, and accounted for the highest share in 2016.
The antifungal drugs occupied about two-sevenths share of the total antifungal drugs market by dosage form in 2016 and is expected to retain its dominant share throughout the forecast period.
China occupied one-fifth share of the total Asia-Pacific antifungal drugs market in 2016, registering a CAGR of 4.8% from 2017 to 2023.
The azole drug type dominated the market in 2016, growing at a CAGR of 3.9% from 2017 to 2023.
In 2016, Asia-Pacific and LAMEA collectively accounted for about three-eighths share of the market and is expected to continue this trend throughout the forecast period. Increase in awareness regarding antifungal drugs, availability of these drugs specifically in China, India, and the other developing economies, and growth in awareness regarding the fungal diseases drive the market. Moreover, the massive target population and growth in economy catering to the establishment of healthcare facilities boost the market.
The report provides a comprehensive analysis of the key players operating in the global antifungal drugs market such as Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc.
The other players of the global antifungals drugs market include Astellas Pharma, Inc., Sigma-Aldrich Corporation, Agilent Technologies, Inc., Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Kramer Laboratories, Basilea Pharmaceutical Ltd., Valeant Pharmaceuticals International, Inc., and Tecan Group.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.